# Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)

> **NCT00769171** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 364 (actual)

## Conditions studied

- Infection, Intra-abdominal

## Interventions

- **DRUG:** Avelox (Moxifloxacin, BAY12-8039)
- **DRUG:** Ceftriaxone + Metronidazole

## Key facts

- **NCT ID:** NCT00769171
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2006-12
- **Final completion:** 2007-01
- **Target enrollment:** 364 (ACTUAL)
- **Last updated:** 2014-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00769171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00769171, "Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00769171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*